AQEMIA
- 01/02/2024
- Series A
- $30,000,000
Aqemia is a pharmatech company using quantum physics and artificial intelligence to transform the drug discovery process. With a unique proprietary technology that preclude the use of experimental data, our pipeline scales the drug discovery process at an unprecedented pace, generating an exhaustive number of new drug candidates.
We are hiring! Check our career website: https://jobs.lever.co/aqemia.com
Blog Posts on: https://medium.com/aqemia
- Industry Biotechnology Research
- Website https://www.aqemia.com/
- LinkedIn https://www.linkedin.com/company/aqemia/
Related People
Maximilien LevesqueFounder
As the CEO and Co-Founder of Aqemia, I lead a tech x bio company that leverages quantum-inspired AI and machine learning to invent innovative molecules and maximize their chance of success in pharmaceutical research. With more than 10 years of experience as a scientist and entrepreneur in drug discovery, I have a strong background in chemical physics, statistical mechanics, and theoretical chemistry, as well as a passion for applying cutting-edge technologies to solve real-world problems.
Prior to founding Aqemia, I was a research group leader for 6 years at École normale supérieure, Paris, where I developed novel algorithms and methods based on quantum mechanics and generative AI for drug discovery. I also held various research and teaching positions at prestigious institutions such as Ecole normale supérieure, CNRS, CEA, EDF R&D, Sorbonne University, Oxford, and Cambridge. I own a PhD in quantum mechanics from the French atomic energy center, and I have published multiple papers in leading journals, as well as received several honors and awards for my work.
My mission is to accelerate the discovery of new drugs and therapies that can improve human health and well-being.